Search research articles
Contact Us
Filters
Showing results (371-380 of 391) with videos related to
Page
of 40
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
April 5, 2023
Longitudinal head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease
Charles D Chen, Austin McCullough, Brian Gordon, et al.
Acta Neuropathologica Communications
|
April 26, 2023
Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease
Muhammad Ali, Derek B Archer, Priyanka Gorijala, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 7, 2013
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
Tammie L S Benzinger, Tyler Blazey, Clifford R Jack, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial
Austin McCullough, Charles D Chen, Brian A Gordon, et al.
Brain : a Journal of Neurology
|
February 4, 2025
The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onset
Haiyan Liu, Thomas W Marsh, Xinyu Shi, et al.
Acta Neuropathologica
|
June 3, 2025
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease
Charles D Chen, Erin E Franklin, Yan Li, et al.
The Lancet. Neurology
|
April 17, 2024
Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
Julie K Wisch, Nicole S McKay, Anna H Boerwinkle, et al.
JAMA Neurology
|
April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
Olivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Aging Cell
|
June 9, 2023
Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's disease
Stephanie A Schultz, Zahra Shirzadi, Aaron P Schultz, et al.
Annals of Neurology
|
September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Nelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Page
of 40
Search research articles
Search
Showing results (371-380 of 391) with videos related to
Sort By:
Page
of 40
European Journal of Nuclear Medicine and Molecular Imaging
|
April 5, 2023
Longitudinal head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease
Charles D Chen, Austin McCullough, Brian Gordon, et al.
Acta Neuropathologica Communications
|
April 26, 2023
Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease
Muhammad Ali, Derek B Archer, Priyanka Gorijala, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 7, 2013
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
Tammie L S Benzinger, Tyler Blazey, Clifford R Jack, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial
Austin McCullough, Charles D Chen, Brian A Gordon, et al.
Brain : a Journal of Neurology
|
February 4, 2025
The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onset
Haiyan Liu, Thomas W Marsh, Xinyu Shi, et al.
Acta Neuropathologica
|
June 3, 2025
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease
Charles D Chen, Erin E Franklin, Yan Li, et al.
The Lancet. Neurology
|
April 17, 2024
Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
Julie K Wisch, Nicole S McKay, Anna H Boerwinkle, et al.
JAMA Neurology
|
April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
Olivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Aging Cell
|
June 9, 2023
Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's disease
Stephanie A Schultz, Zahra Shirzadi, Aaron P Schultz, et al.
Annals of Neurology
|
September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Nelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Page
of 40